Patents by Inventor David W. Mullins

David W. Mullins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11819543
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
  • Publication number: 20220236284
    Abstract: The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.
    Type: Application
    Filed: December 6, 2021
    Publication date: July 28, 2022
    Inventors: Harold David Gunn, David W. Mullins, Shirin Kalyan, Momir Bosiljcic, Monan Angela Zhang, Mark Bazett, Marcel Thalen, Dermot McGovern, Boyko Traychev Kabakchiev, Ho Pan Sham
  • Patent number: 11226340
    Abstract: The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 18, 2022
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, David W. Mullins, Shirin Kalyan, Momir Bosiljcic, Monan Angela Zhang, Mark Bazett, Marcel Thalen, Dermot McGovern, Boyko Traychev Kabakchiev, Ho Pan Sham
  • Publication number: 20210138057
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Application
    Filed: January 21, 2021
    Publication date: May 13, 2021
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
  • Patent number: 10946083
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 16, 2021
    Assignee: Qu Biologies Inc.
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
  • Publication number: 20210052645
    Abstract: Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.
    Type: Application
    Filed: December 28, 2018
    Publication date: February 25, 2021
    Inventors: Harold David Gunn, David W. Mullins, Mark Bazett, Shirin Kalyan
  • Publication number: 20190247484
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 15, 2019
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
  • Publication number: 20190134172
    Abstract: The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Inventors: Harold David Gunn, David W. Mullins, Shirin Kalyan, Momir Bosiljcic, Monan Angela Zhang, Mark Bazett, Marcel Thalen, Dermot McGovern, Boyko Traychev Kabakchiev, Ho Pan Sham
  • Patent number: 10251946
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 9, 2019
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
  • Publication number: 20170087237
    Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
    Type: Application
    Filed: May 1, 2015
    Publication date: March 30, 2017
    Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins